• PharmaEssentia's Ropeg secured essential thrombocythemia approvals in the U.S. and Asia, including Taiwan, Japan and China.
• The essential thrombocythemia indication remains unapproved in Europe, where AOP handles regulatory submissions under a 2009 licensing agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaEssentia Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611030656BIZWIRE_USPR_____20261103_BW485400) on November 03, 2026, and is solely responsible for the information contained therein.